MedTrace Logo

Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma

NCT02768389 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-03-15

No results posted yet for this study

Summary

Patients may participate in this research study if they have glioblastoma. (a brain tumor) that has come back after being treated. Standard treatment for this cancer is a chemotherapy drug called bevacizumab. This research study involves bevacizumab in combination with a special diet called the Modified Atkins Diet (MAD).

The purpose of this study is to research if patients can stay on the MAD when it is added to the standard bevacizumab treatment.

Conditions

Interventions

DRUG

Bevacizumab

Subjects receive Bevacizumab as standard of care

BEHAVIORAL

Modified Atkins Diet

The modified Atkins diet (MAD) includes high fat, unlimited protein, and restricted carbohydrates (\< 20gm/day).

Sponsors & Collaborators

  • University of Cincinnati

    collaborator OTHER

  • OhioHealth Research Institute

    collaborator UNKNOWN

  • Case Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Lisa Rogers, DO · University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-06
Primary Completion
2018-11-30
Completion
2018-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02768389 on ClinicalTrials.gov